Galectin Therapeutics (GALT) Net Cash Flow (2010 - 2026)

Galectin Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 53.13% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at $6.7 million (up 141.3% YoY), while the FY2025 annual figure was $2.6 million, up 124.43% from the prior year.
• Net Cash Flow was -$3.6 million for Q1 2026 at Galectin Therapeutics, down from $6.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $6.3 million in Q2 2025 to a low of -$11.9 million in Q4 2024.
• Historically, Net Cash Flow has averaged -$1.5 million across 5 years, with a median of -$793000.0 in 2023.
• Biggest YoY gain for Net Cash Flow was 1143.11% in 2024; the steepest drop was 326.87% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $2.8 million in 2022, then soared by 90.62% to $5.3 million in 2023, then tumbled by 326.87% to -$11.9 million in 2024, then soared by 151.4% to $6.1 million in 2025, then tumbled by 158.81% to -$3.6 million in 2026.
• The last three Net Cash Flow figures came in at -$3.6 million (Q1 2026), $6.1 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.